Generic name:infliximab-qbtx (intravenous route) [ in-FLIX-i-mab-- qbtx ]
Drug class:TNF alfa inhibitors
Medically reviewed by Drugs.com. Last updated on Oct 3, 2021.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. Discontinue infliximab-qbtx if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting infliximab-qbtx. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn disease or ulcerative colitis, most of whom were adolescent or young adult males .
Commonly used brand name(s)
In the U.S.
- Ixifi
Pharmacologic Class: Infliximab
Uses for Ixifi
Infliximab-qbtx injection is used to treat Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. Infliximab-qbtx injection is a monoclonal antibody that works to enhance and improve the immune system.
This medicine is available only with your doctor's prescription.
Before using Ixifi
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
